McKane W, Lee J, Preston R, van Dam M, Cairns T, Taube D
The Brent Laboratory, St Mary's Hospital, London, UK.
Transplantation. 2000 Oct 15;70(7):1085-93. doi: 10.1097/00007890-200010150-00016.
Xenografts that have been protected from hyperacute rejection (HAR) are termed accommodated if they are not then rejected despite the presence of xenoantibody. It has been proposed that IgG may confer resistance to complement dependent cytotoxicity (CDC), a conventional in vitro marker of accommodation. We hypothesized that noncytotoxic IgG2 anti-Galalpha1-3Gal was responsible for this effect.
We purified IgG anti-Galalpha1-3Gal from pooled human normal immunoglobulin and three sera, by elution from protein G and Galalpha1-3Gal-R immunoadsorbents. The eluates were IgM free and > or =95% IgG2. They bound to Galalpha1-3Gal, porcine aortic endothelial cells (PAEC) and lymphocytes. It was not possible to block IgM binding to PAEC or lymphocytes using IgG anti-Galalpha1-3Gal (200 microg/ml). The eluates were noncytotoxic in micro-CDC assays. To investigate accommodation, PAEC were cultured with subsaturating doses of the four IgG eluates for up to 144 hr. Resistance of nontrypsinized PAEC to CDC by human serum was measured in a cell viability assay. PAEC were not rendered resistant to CDC in any of the experiments. To investigate the possibility that accommodation might be induced by non-Galalpha1-3Gal IgG, the experiments were repeated using HNIg, again with no protection demonstrated.
Using primary PAEC monolayers, we were unable to induce resistance to CDC with human normal immunoglobulin and its IgG2 anti-Gabeta1-3Gal subset. This contradicts previous experiments using trypsinized, immortalized cells. Although resistance to CDC is not an ideal marker of accommodation, the detrimental effects of IgG make it unlikely that it will become a useful clinical means of inducing accommodation.
已免受超急性排斥反应(HAR)影响的异种移植物,如果尽管存在异种抗体但随后未被排斥,则称为适应性异种移植物。有人提出,IgG可能赋予对补体依赖性细胞毒性(CDC)的抗性,这是适应性的一种传统体外标志物。我们假设非细胞毒性的IgG2抗Galα1-3Gal负责这种效应。
我们通过从蛋白G和Galα1-3Gal-R免疫吸附剂上洗脱,从混合的人正常免疫球蛋白和三份血清中纯化出抗Galα1-3Gal IgG。洗脱物不含IgM且≥95%为IgG2。它们与Galα1-3Gal、猪主动脉内皮细胞(PAEC)和淋巴细胞结合。使用抗Galα1-3Gal IgG(200μg/ml)无法阻断IgM与PAEC或淋巴细胞的结合。洗脱物在微量CDC试验中无细胞毒性。为了研究适应性,将PAEC与四种IgG洗脱物的亚饱和剂量培养长达144小时。在细胞活力测定中测量未用胰蛋白酶处理的PAEC对人血清CDC的抗性。在任何实验中,PAEC均未对CDC产生抗性。为了研究非Galα1-3Gal IgG诱导适应性的可能性,使用人天然免疫球蛋白重复实验,同样未显示出保护作用。
使用原代PAEC单层,我们无法用人正常免疫球蛋白及其IgG2抗Galβ1-3Gal亚群诱导对CDC的抗性。这与之前使用胰蛋白酶处理的永生化细胞的实验结果相矛盾。尽管对CDC的抗性不是适应性的理想标志物,但IgG的有害作用使其不太可能成为诱导适应性的有用临床手段。